Show simple item record

Cognitive behavioral therapy program for cannabis use cessation in first-episode psychosis patients: study protocol for a randomized controlled trial

dc.contributor.authorGonzález Ortega, Itxaso
dc.contributor.authorEcheburúa Odriozola, Enrique ORCID
dc.contributor.authorGarcía-Alocén, Adriana
dc.contributor.authorVega, Patricia
dc.contributor.authorGonzález Pinto Arrillaga, Ana María ORCID
dc.date.accessioned2019-04-10T10:40:34Z
dc.date.available2019-04-10T10:40:34Z
dc.date.issued2016-07-29
dc.identifier.citationTrials 17 : (2016) // Article ID 372es_ES
dc.identifier.issn1745-6215
dc.identifier.urihttp://hdl.handle.net/10810/32407
dc.description.abstractBackground: The high rate of cannabis use among patients with first-episode psychosis (FEP), as well as the associated negative impact on illness course and treatment outcomes, underlines the need for effective interventions in these populations. However, to date, there have been few clinical treatment trials (of pharmacological or psychological interventions) that have specifically focused on addressing comorbid cannabis use among these patients. The aim of this paper is to describe the design of a study protocol for a randomized controlled trial in which the objective is to assess the efficacy of a specific cognitive behavioral therapy program for cannabis cessation in patients with FEP compared to standard treatment (psychoeducation). Methods/design: This is a single-blind randomized study with 1 year of follow-up. Patients are to be randomly assigned to one of two treatments: (1) specific cognitive behavioral therapy for cannabis cessation composed of 1-hour sessions once a week for 16 weeks, in addition to pharmacological treatment scheduled by the psychiatrist, or (2) a control group (psychoeducation + pharmacological treatment) following the same format as the experimental group. Participants in both groups will be evaluated at baseline (pre-treatment), at 16 weeks (post-treatment), and at 3 and 6 months and 1 year of follow-up. The primary outcome will be that patients in the experimental group will have greater cannabis cessation than patients in the control group at post-treatment. The secondary outcome will be that the experimental group will have better clinical and functional outcomes than the control group. Discussion: This study provides the description of a clinical trial design based on specific cognitive behavioral therapy for cannabis cessation in FEP patients, aiming to improve clinical and functional outcome, as well as tackling the addictive disorder.es_ES
dc.description.sponsorshipThis study is funded by the Spanish Ministry of Economy and Competitiveness, through the Carlos III Health Institute (ISCIII), and the European Regional Development Fund (ERDF) (PI13/02252).es_ES
dc.language.isoenges_ES
dc.publisherBiomed Centrales_ES
dc.relationinfo:eu-repo/grantAgreement/MINECO/PI13/02252es_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectcannabises_ES
dc.subjectfirst-episode psychosises_ES
dc.subjectpsychological treatmentes_ES
dc.subjectage-of-onsetes_ES
dc.subject1st episode psychosises_ES
dc.subjectclinical high-riskes_ES
dc.subjectmedication adherencees_ES
dc.subjectpredictive-validityes_ES
dc.subjectanandamide levelses_ES
dc.subjectuse disorderses_ES
dc.subjectsubstance usees_ES
dc.subjectyoung-peoplees_ES
dc.subjectschizophreniaes_ES
dc.titleCognitive behavioral therapy program for cannabis use cessation in first-episode psychosis patients: study protocol for a randomized controlled triales_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holderThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.es_ES
dc.rights.holderAtribución 3.0 España*
dc.relation.publisherversionhttps://trialsjournal.biomedcentral.com/articles/10.1186/s13063-016-1507-xes_ES
dc.identifier.doi10.1186/s13063-016-1507-x
dc.departamentoesNeurocienciases_ES
dc.departamentoesPersonalidad, evaluación y tratamiento psicológicoes_ES
dc.departamentoeuNeurozientziakes_ES
dc.departamentoeuNortasuna, balioespena eta psikologia tratamenduaes_ES


Files in this item

Thumbnail
Name:
license_rdf
Size:
914bytes
Format:
application/rdf+xml
View/Open
Thumbnail
Name:
document.pdf
Size:
478.3Kb
Format:
PDF
Description:
Artículo principal
View/Open

This item appears in the following Collection(s)

Show simple item record

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Except where otherwise noted, this item's license is described as This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.